Drugs / autologous myoblasts
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01355133 | Aug 2009 → Feb 2011 | female stress incontinence | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02878694 | Nov 2019 → Oct 2020 | oculopharyngeal muscular dystrophy, ptosis | University Hospital, Caen | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous myoblasts | “Autologous myoblasts isolated from a biceps muscle sample were injected under transurethral ultrasound guidance into the external urethral sphincter of 38 female patients.” PMID 22342057 ↗ Feb 20121“30 million autologous myoblasts in 6 intramuscular injections” NCT02878694 ↗ |
| Action | Restore | “restore muscle function levator muscle of the upper eyelid by providing a registry of autologous myoblasts” NCT02878694 ↗ |
| Modality | Cell therapy | “Autologous myoblasts isolated from a biceps muscle sample were injected under transurethral ultrasound guidance into the external urethral sphincter of 38 female patients.” PMID 22342057 ↗ Feb 2012 |
| Route | Other | “injected under transurethral ultrasound guidance into the external urethral sphincter” PMID 22342057 ↗ Feb 2012 |